Qnexa
FDA clears Arena and Eisai’s obesity drug
June 28, 2012Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity
Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …
Obesity drugs vie for approval as FDA panel backs lorcaserin
May 14, 2012Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity
An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …
Obesity drug supported by FDA panel
February 23, 2012Sales and Marketing FDA, Qnexa, Vivus, Xenical, obesity
Vivus’ obesity drug Qnexa has been supported by an FDA panel, two years after it was knocked back by the …
Takeda obesity drug falters at phase II
March 18, 2011Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
